Hangzhou Alltest Biotech Co. Ltd. A (688606) - Total Liabilities
Based on the latest financial reports, Hangzhou Alltest Biotech Co. Ltd. A (688606) has total liabilities worth CN¥226.79 Million CNY (≈ $33.19 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Hangzhou Alltest Biotech Co. Ltd. A to measure how many days the company can operate on defensive assets alone.
Hangzhou Alltest Biotech Co. Ltd. A - Total Liabilities Trend (2016–2025)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Check Hangzhou Alltest Biotech Co. Ltd. A liquidity resilience to evaluate the company's liquid asset resilience ratio.
Hangzhou Alltest Biotech Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Hangzhou Alltest Biotech Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Everjoy Health Group Co Ltd
SHE:002162
|
China | CN¥1.17 Billion |
|
WhiteFiber, Inc. Ordinary Shares
NASDAQ:WYFI
|
USA | $74.02 Million |
|
Perusahaan Perkebunan London Sumatra Indonesia Tbk PT
JK:LSIP
|
Indonesia | Rp1.77 Trillion |
|
SENCO GOLD LTD
NSE:SENCO
|
India | Rs45.48 Billion |
|
Shanghai Jin Jiang International Industrial Investment Co Ltd A
SHG:600650
|
China | CN¥1.08 Billion |
|
Guangdong Hybribio Biotech Co Ltd
SHE:300639
|
China | CN¥475.29 Million |
|
BRASKEM PFD ADR/2 O.N.
F:BRD
|
Germany | €98.38 Billion |
|
Sturm Ruger & Company Inc
NYSE:RGR
|
USA | $74.49 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Hangzhou Alltest Biotech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hangzhou Alltest Biotech Co. Ltd. A balance sheet assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou Alltest Biotech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou Alltest Biotech Co. Ltd. A (2016–2025)
The table below shows the annual total liabilities of Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥296.09 Million ≈ $43.33 Million |
-2.15% |
| 2024-12-31 | CN¥302.60 Million ≈ $44.28 Million |
+6.36% |
| 2023-12-31 | CN¥284.50 Million ≈ $41.63 Million |
-46.20% |
| 2022-12-31 | CN¥528.80 Million ≈ $77.38 Million |
-28.03% |
| 2021-12-31 | CN¥734.71 Million ≈ $107.51 Million |
+311.73% |
| 2020-12-31 | CN¥178.45 Million ≈ $26.11 Million |
+354.04% |
| 2019-12-31 | CN¥39.30 Million ≈ $5.75 Million |
-0.42% |
| 2018-12-31 | CN¥39.47 Million ≈ $5.78 Million |
-24.05% |
| 2017-12-31 | CN¥51.97 Million ≈ $7.60 Million |
+60.31% |
| 2016-12-31 | CN¥32.42 Million ≈ $4.74 Million |
-- |
About Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more